Erin McEvoy

The transition to Polyendocrine Metabolic Ovarian Syndrome (PMOS) signals a potential shift toward multisystem metabolic interventions in the women's health category.

The Food and Drug Administration has formalized a new post-market assessment process for chemicals used in food and simultaneously opened reassessments of butylated hydroxytoluene and azodicarbonamide,

The 90% TG Premium fish oil with 900 mg/g EPA/DHA enables high-potency supplement formulations with smaller capsule sizes while maintaining sensory profiles.

In this preview of the upcoming The Outlook on Women's Wellness, Stacey Smith, DC, Senior Medical Science Liaison at Gnosis by Lesaffre, shares insights into product development for women's health solutions.

Arla Foods Ingredients introduced high-protein food and beverage concepts at Vitafoods Europe, targeting the fast-growing GLP-1 companion weight-management market.

Symrise and Probi expanded formulation horizons at Vitafoods Europe, launching stable postbiotics and clinical botanicals for active nutrition and wellness.

Study shows plant-based Ahiflower oil outperforms Echium oil in boosting tissue EPA and maintaining brain and heart DHA levels.

Dr. Thais Aliabadi, OBGYN, explains why the renaming of PCOS to PMOS is vital for addressing the root metabolic, endocrine, and whole-body health symptoms women face.

Clinical research, botanical innovation, and targeted delivery formats are reshaping the menopause supplement market as nutraceutical companies develop science-backed solutions for sleep, muscle health, and women's wellness.

Learn how the official rename of the condition opens new opportunities for nutraceutical brands targeting systemic metabolic wellness.